-
-
-
-
-
-
-
Corcept presents survival data for ovarian cancer drug Lifyorli
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Lowered to $67 at H.C. Wainwright
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Lowered to $90 at H.C. Wainwright
-
-
-
-
-
-
-
UBS Starts Corcept Therapeutics (CORT) at Neutral
-
-
-
-
-
-
-
Corcept to present ROSELLA trial data on ovarian cancer at ESMO 2025
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) Presents Results from Phase 2 Study of Dazucorilant
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) call put ratio 20 calls to 1 put with a focus on May 75 calls and June 80 calls as share price up 7.3%
-
408,609 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

